Literature DB >> 2817678

Treatment of depressed tinnitus patients with nortriptyline.

M D Sullivan1, R A Dobie, C S Sakai, W J Katon.   

Abstract

Patients disabled by tinnitus show a high prevalence of major depression. Furthermore, tinnitus produces patterns of disability similar to those produced by major depression. To explore further this link between tinnitus and depression, and to investigate the efficacy of treating depression in the treatment of tinnitus, a single-blind, placebo-washout, nonrandomized pilot study of the tricyclic antidepressant nortriptyline (hydrochloride) was undertaken in disabled tinnitus patients who also met diagnostic criteria for major depression. Nineteen patients began the study, two responded to placebo, and two dropped out prior to completion. Fourteen considered their tinnitus improved, and 12 chose to continue taking nortriptyline after the study. Depression severity decreased, on the average, by 65% (p less than .0001). Tinnitus loudness measured by audiometric matching decreased by a mean of 10 dB or 50% (p less than .02). Self-reports of tinnitus loudness and severity, somatic and psychologic symptoms, and psychosocial dysfunction all showed significant improvement with treatment. These results suggest that what initially appears to be an irreversible otologic disability in these patients may be in large part a reversible psychiatric disability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817678     DOI: 10.1177/000348948909801107

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  13 in total

Review 1.  Targeting inhibitory neurotransmission in tinnitus.

Authors:  Ben D Richardson; Thomas J Brozoski; Lynne L Ling; Donald M Caspary
Journal:  Brain Res       Date:  2012-02-14       Impact factor: 3.252

2.  PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD.

Authors:  R Salvi; E Lobarinas; W Sun
Journal:  Drugs Future       Date:  2009       Impact factor: 0.148

Review 3.  Antidepressants for patients with tinnitus.

Authors:  Paolo Baldo; Carolyn Doree; Paola Molin; Don McFerran; Sara Cecco
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

4.  The Effects of Quinine on Neurophysiological Properties of Dopaminergic Neurons.

Authors:  Li Zou; Yingchao Xue; Michael Jones; Thomas Heinbockel; Mingyao Ying; Xiping Zhan
Journal:  Neurotox Res       Date:  2017-12-29       Impact factor: 3.911

Review 5.  Tinnitus Retraining Therapy (TRT) for tinnitus.

Authors:  John S Phillips; Don McFerran
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

6.  Methodological aspects of clinical trials in tinnitus: a proposal for an international standard.

Authors:  Michael Landgrebe; Andréia Azevedo; David Baguley; Carol Bauer; Anthony Cacace; Claudia Coelho; John Dornhoffer; Ricardo Figueiredo; Herta Flor; Goeran Hajak; Paul van de Heyning; Wolfgang Hiller; Eman Khedr; Tobias Kleinjung; Michael Koller; Jose Miguel Lainez; Alain Londero; William H Martin; Mark Mennemeier; Jay Piccirillo; Dirk De Ridder; Rainer Rupprecht; Grant Searchfield; Sven Vanneste; Florian Zeman; Berthold Langguth
Journal:  J Psychosom Res       Date:  2012-06-22       Impact factor: 3.006

Review 7.  Emerging pharmacotherapy of tinnitus.

Authors:  Berthold Langguth; Richard Salvi; Ana Belén Elgoyhen
Journal:  Expert Opin Emerg Drugs       Date:  2009-12       Impact factor: 4.191

Review 8.  [Current aspects of tinnitus and depression].

Authors:  V Kratzsch; G Goebel
Journal:  HNO       Date:  2018-03       Impact factor: 1.284

9.  An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.

Authors:  Hyunah Shin; Suehyun Lee
Journal:  BMC Med Inform Decis Mak       Date:  2021-05-17       Impact factor: 2.796

Review 10.  The Management and Outcomes of Pharmacological Treatments for Tinnitus.

Authors:  Devon Beebe Palumbo; Kathleen Joos; Dirk De Ridder; Sven Vanneste
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.